Birmingham, AL, April 17th 2019 – The U.S. Food and Drug Administration (FDA) has chosen to partner with Vulcan Biosciences Inc. (formerly Vulcan Analytical) for cutting-edge blood protein research in sickle cell disease.  The critical findings from this research were published in the prestigious Journal of Clinical Investigation Insight and highlighted on the FDA website (see below).  Several new findings for sickle cell disease described in the paper were identified with Vulcan Biosciences software platform, PROTALIZER™, including the first evidence of ubiquitinylation of hemoglobin in sickle cell disease.  The study was conducting in the laboratory of Dr. Abdu Alayash, a Lab Chief in the Center for Biologics Evaluation and Research in collaboration with Dr. Michael Heaven, Chief Scientific Officer of Vulcan Biosciences. According to Dr. Heaven, “We’ve forged a great research partnership with the FDA. They were quick to recognize the power of our platform for making new discoveries, and this important research success is the result.”